US startup acquisitions are on course for a record year, with spending propelled by a single artificial intelligence mega-deal that has reshaped expectations for what a private company exit can look like. American companies have spent close to $120 billion acquiring venture-backed startups so far in 2026, putting the market on pace to surpass last year's historical highs by a wide margin. Bankers and investors tracking the figures describe a market that has moved past its post-pandemic slowdown and into a period of aggressive consolidation, with technology and biotechnology firms leading the charge.

The scale of this year's activity owes much to one transaction. SpaceX's $60 billion acquisition of Cursor, the AI coding startup, and its parent company Anysphere accounts for roughly half of all spending recorded this year. The deal closed shortly after SpaceX completed its own initial public offering, a sequence that allowed Elon Musk's rocket company to deploy fresh capital almost immediately into one of the hottest corners of the software industry.

The numbers involved place the Cursor deal in a category of its own. It stands as the largest acquisition of a startup in history, nearly doubling the previous record of $32 billion set by Google's purchase of cybersecurity firm Wiz. For comparison, Facebook's acquisition of WhatsApp in 2014, long held up as a benchmark for tech industry excess, came in at $19 billion, a figure that now looks modest set against the scale of money moving through Silicon Valley a decade later.

While the Cursor deal dominates the headlines, biotechnology has provided the second major engine behind this year's surge. Eli Lilly has been particularly active, striking a series of acquisitions aimed at expanding its pipeline in gene therapy and RNA-based treatments. The pharmaceutical giant agreed to pay up to $7 billion for Kelonia Therapeutics, a gene-therapy developer, alongside a $2.4 billion deal for RNA specialist Orna Therapeutics and a further $2.3 billion buyout of Ajax Therapeutics.

These figures come with an important caveat. The headline numbers attached to biotech acquisitions typically represent maximum potential payouts rather than guaranteed cash transfers. Much of the money is structured around milestone payments, meaning Eli Lilly will only pay the full amounts if the acquired companies hit specific clinical trial results and commercialisation targets. The actual sums changing hands could therefore be considerably lower, depending on how the science and regulatory approvals unfold over the coming years.

Beyond the headline deals in tech and pharmaceuticals, this year's acquisition spree has touched a wide range of industries. The next tier of major transactions ranges between $2 billion and just over $5 billion, illustrating how broadly the appetite for consolidation has spread. Capital One agreed to absorb Brex, the corporate card provider, in a deal worth $5.15 billion, extending the bank's push into business financial services. Qualcomm, meanwhile, made a strategic move into artificial intelligence hardware with its $4 billion purchase of chip manufacturer Modular.

Enterprise software has seen its own share of activity. Salesforce acquired Fin, an AI customer-experience firm, for $3.6 billion, while Autodesk struck an identically valued deal to purchase MaintainX, an industrial AI platform. The matching price tags on these two transactions, arrived at independently, underline how competitive valuations have become for companies offering AI-driven tools to enterprise customers.

As the second quarter draws to a close, dealmakers see little sign of the momentum slowing. Several bankers have suggested further high-profile transactions are already in the pipeline, particularly in sectors where AI capabilities remain scarce and in demand. Whatever happens in the second half of the year, 2026 has already secured its place as one of the most lucrative periods on record for startup founders and venture investors seeking an exit.

‍